HHS Makes 60K Replacement Doses Of Bebtelovimab Available For Uninsured

HHS unveiled a new initiative to help uninsured and underinsured Americans access the COVID-19 treatment bebtelovimab and to smooth out the transition from reliance on drugs purchased by the government to reliance on the commercial marketplace. Under the program, effective immediately, providers that treat an uninsured or underinsured patient with a commercially procured dose of bebtelovimab can seek a free replacement dose from HHS. The department is making 60,000 doses of the drug available to providers and HHS expects the...